Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAL: Octreotide capsules in acromegaly
NCT03252353Phase 3Unknown
- Sponsor
- Chiasma
- Start
- Sep 2017
- Primary completion
- Jun 2019
- Modality
- Peptides
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in acromegaly comparing Octreotide capsules with Placebo (2 arms). Primary endpoint: Proportion of Patients Who Maintain Their Biochemical Response at 36 weeks. Status: unknown.
02
Drugs
octreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT03252353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03252353.